This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Kate Bingham
Former Chair U.K. Vaccine Taskforce, Managing Partner at SV Health Managers LLP

Profile

In her 29 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.

Kate co-leads biotech investments and activities and her investments include small-molecule, biotherapeutic and gene therapy drug discovery and development projects as well as drug discovery platforms in a broad range of clinical areas.

Kate played an active role in setting up the Dementia Discovery Fund (DDF), an SV managed fund, and serves on the DDF Investment Committee.

Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm.

Outside of SV, Kate won the Lifetime Achievement Award, presented by the BioIndustry Association UK in January 2017. She also serves on the Board of the Francis Crick Institute. At weekends Kate spends time in Wales where she rides horses and mountain bikes, grows vegetables and competes in bog snorkelling competitions.

In May 2020 Kate was appointed Chair of the UK Vaccine Taskforce reporting to the Prime Minster to lead UK efforts to find and manufacture a COVID-19 vaccine on a 6 month engagement.

Academic credentials
First class degree, Biochemistry, University of Oxford; MBA, Harvard Business School (Baker Scholar)

Agenda Sessions

  • In conversation with the COVID-19 leaders: The UK perspective

    9:00am